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Abstract
Aim: To examine the preference for two dosing regimens of 20 mg of tadalafil, on demand or three times per week,
in men affected with erectile dysfunction (ED) in Italy.  Methods: Scheduled Use versus on demand Regimen Evalu-
ation (SURE) is a multicenter, crossover and open-label study, involving 94 urology centers in Italy.  Patients aged
18 years or older affected with ED for at least 3 months were enrolled and randomized to 20 mg of tadalafil treatment
on demand or three times per week for 5–6 weeks.  After a 1-week washout, patients were crossed over to the
alternate regimen for 5–6 weeks.  A treatment preference question was used to determine the preferred treatment
regimen. International Index of Erectile Function (IIEF) and Sexual Encounter Profile (SEP) questionnaire were used
as efficacy measures.  Results: A total of 1 058 men (mean age 54.8 years), were randomized to treatment.  Overall,
59.1% of patients preferred the on-demand regimen and 41.9% preferred the three times per week dosing.  Both
regimens were efficacious and well tolerated.  Although a statistically higher improvement of the IIEF erectile function
(IIEF-EF) domain score and the SEP questionnaire was reported for the three times per week compared to the on-
demand treatment regimen, this difference was numerically minimal and lacking in clinical significance.  Conclusion:
Tadalafil is effective and well tolerated whether used on demand or three times per week.  Patients should be given the
option to choose the best treatment regimen according to personal needs and preferences.  (Asian J Androl 2007 May;
9: 395–402)
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1    Introduction
Tadalafil is an effective and well tolerated phosphodi-
esterase type 5 (PDE5) inhibitor, approved in more than
100 countries for the treatment of erectile dysfunction
(ED).  Compared to sildenafil citrate and vardenafil HCL,
tadalafil presents unique pharmacokinetic properties, as
it has been shown to be effective up to 36 hours from
dosing [1].  This characteristic has opened new thera-
peutic possibilities in the treatment of ED with respect to
other shorter half-life PDE5 inhibitors that allow patients
to engage in sexual intercourse within a few hours of
dosing.  Using traditional “on-demand” dosing, the long-
lasting effectiveness of tadalafil allows patients to en-
gage in sexual intercourse far after dosing, reducing the
need for strictly planning sexual activity [2].
Furthermore, dosing of tadalafil on a regular basis has
been evaluated.  The Scheduled Use versus on demand
Regimen Evaluation (SURE) study, including more than 4
000 patients in 14 European countries, has demonstrated
that a three-time per week regimen of tadalafil is as affec-
tive and well tolerated as the on-demand regimen and that
more than 42.2% of patients prefer the fixed dosing treat-
ment when allowed to choose [3].  However, the pattern
of choice was independent of patients’ baseline
characteristics, like ED severity and etiology and the rea-
sons for preference were related to individual cultural and
psychosocial factors, which might differ among countries.
We analyzed the Italian data subset of the SURE study to
evaluate the efficacy and safety of a fixed dosing treat-
ment with 20 mg of tadalafil  and to determine patient pref-
erence for an on-demand or a three-time per week regimen.
2    Materials and methods
SURE was a randomized, crossover and open-label
study, involving 94 urology centers in Italy from Octo-
ber 2002 to July 2003.  Patients were included if aged at
least 18 years and affected with ED of any severity and
etiology for at least 3 months.  Patients had to be en-
gaged in a stable heterosexual relationship throughout the
study period and had to agree not to use any other ED
treatment from the beginning of the run-in period to
96 hours after the final visit.  Exclusion criteria were:
use of nitrates, cancer chemotherapy or antiandrogens
and congestive hearth failure.  Notably, patients previ-
ously assuming other commercially available PDE5 in-
hibitors were not excluded from the study.
The study design (Figure 1) has already been de-
scribed in detail [2].  Briefly, after signing an informed
consent, each patient underwent a screening evaluation,
including a comprehensive review of medical history,
physical examination, laboratory safety tests and
electrocardiogram, and started a 3–4 week run-in, treat-
ment-free period phase.  Patients were then randomized
to assume 20 mg of tadalafil according to either a “on-
demand” or “three times per week” regimen for 5–
6 weeks (Treatment I).  Patients did not have to observe
any restriction on food or alcohol.  Patients randomized
to the “on-demand” regimen were instructed not to ex-
ceed one dose per day.  Patients randomized to the “three
times per week” regimen were instructed to assume
20 mg of tadalafil on Monday, Wednesday and Friday
(subgroup A) or on Tuesday, Thursday and Saturday
(subgroup B) at the same hour, independently of sexual
activity.  After a 1-week washout period, patients were
switched to the other treatment regimen for 5–6 weeks
(Treatment II), in a cross-over fashion.  At the comple-
tion of the second treatment phase, patients were asked
to choose the treatment regimen for the extension phase,
which was for a required duration of at least 14 days.
Efficacy measures were the International Index of
Erectile Function (IIEF) and the Sexual Encounter Pro-
file (SEP) questionnaires, collected for each patient at
the baseline and at the end of each treatment phase.  As a
preference measure, at the end of the second treatment
phase patients were also asked to answer the Treatment
Preference Question (TPQ): “Which treatment regimen
did you prefer?” The options were on demand or sched-
uled (three times per week).
Treatment emergent adverse events, defined as events
that first occurred or worsened after the baseline, were
recorded throughout the study period, and all random-
ized patients were included in the safety analysis.
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Statistical analyses were conducted on an intent-to-
treat basis, considering TPQ as the primary endpoint and
efficacy measures IIEF and SEP as secondary endpoints.
The one-sample z-test with a two-sided significance of
0.05 was used to analyze the null hypothesis that equal
proportions of patients prefer the on-demand and three
times per week dosing regimens of tadalafil at the TPQ.
Efficacy variables were evaluated by a cross-over analy-
sis of variance model, using P < 0.05 as a cut-off for
statistical significance.  Protocol and informed consent
documents were approved by ethical review board at
each investigative site.  The study was conducted in ac-
cordance with the protocol, the ethical principles stated
in the Declaration of Helsinki 2002 and applicable laws.
3    Results
3.1  Patients
Out of 1 140 Italian patients signing the informed
consent, 1 058 completed the run-in phase and were ran-
domized to treatment.  All patients answered the prefer-
ence question at the end of the second treatment phase.
A total of 137 patients discontinued the study early
(Figure 2).  The most common reasons for early dis-
continuation were adverse events (4.6%) and lack of
efficacy (2.3%) (Table 1).
Figure 1. Study design. a Study medication (20 mg of tadalafil) taken Monday, Wednesday and Friday; b Study medication (20 mg of
tadalafil) taken on Tuesday, Thursday and Saturday. IIEF, International Index of Erectile Function; SEP, Sexual Encounter Profile; TPQ,
Treatment Preference Question.
Table 1. Summary of reason for study discontinuation during active therapy period by treatment regimen. D/SCH, treatment sequence on
demand regimen (D) then three times per week regimen (SCH); SCH/D: treatment sequence SCH then D.
 Status  D/SCH  SCH/D    Total
                                                                                                 N = 521 (n [%])            N = 537 (n [%])           N = 1058 (n [%])
Protocol completed 455 (87.3) 466 (86.8) 921 (87.1)
Adverse event                                                                                22 (4.2)   27 (5.0)   49 (4.6)
Lack of efficacy, patient perception   14 (2.7)   10 (1.9)   24 (2.3)
Unable to contact patient (lost to follow up)   10 (1.9)     9 (1.7)   19 (1.8)
Personal conflict or other decision of patients   18 (3.5)   21 (3.9)   39 (3.7)
Physician decision     2 (0.4)     2 (0.4)     4 (0.4)
Protocol violation     0     2 (0.4)     2 (0.2)
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Patients’ baseline characteristics are reported in Table 2.
The mean age was 54.8 years, the average weight was
80.3 kg, with an average height of 172.9 cm, and 99.9%
were Caucasian.  Approximately 74% of patients had an
ED history of 1 year or more and the baseline ED severity
was classified as moderate or severe in 58.2% of the
patients.  The ED etiology was clinically determined by
investigators and reported as organic in 34.6%, mixed in
45.8% and psychogenic in 19.6% of patients.
Approximately one-quarter of the patients were smok-
ers and 40.7% of the patients consumed alcohol.
The mean number of doses per week in the three
times per week and the on-demand regimen was 2.33
and 1.89, respectively (P < 0.001)
3.2  Primary endpoint analysis: preference by TPQ
Of the 1 058 subjects who answered the TPQ, 561
(59.1%) chose the on-demand treatment regimen and
389 (40.9%), chose the three times per week regimen.
This same pattern of patient choice was observed re-
gardless of whether patients were randomly assigned to
the three times per week subgroup A (dosing Monday,
Wednesday and Friday) or B (dosing Tuesday, Thurs-
day and Saturday), and regardless of the sequence of
cross-over treatment schedules (on-demand followed by
three times per week or the reverse).  Furthermore, the
analysis of preference based on baseline characteristics
showed that preference was not dependent on the pa-
tients’ age or the etiology, severity and duration of ED.
Table 2. Patient baseline characteristics. †Based on IIEF-EF do-
main scores at baseline. ED, erectile dysfunction; EF, erectile
function; IIEF, International Index of Erectile Function; SEP, Sexual
Encounter Profile.
Characteristic
Age (mean ± SD)   54.8 ± 10.5
Weight (kg) (mean ± SD)   80.3 ± 11.6
Height (cm) (mean ± SD) 172.9 ± 6.9
Race/ethnicity (n [%])
     Caucasian 1 057 (99.9)
     African descent        1 (0.1)
Current smokers (n [%])    274 (25.9)
Current alcohol consumers (n [%])    431 (40.7)
ED severity† (n [%])
     Mild    436 (41.7)
     Moderate    293 (28.0)
     Severe    316 (30.2)
ED etiology (n [%])
     Organic    366 (34.6)
     Mixed    485 (45.8)
     Psychogenic    207 (19.6)
ED duration (n [%])
     < 1 year    274 (26.1)
     > 1 year    784 (74.1)
IIEF-EF domain score at baseline (mean ± SD)   14.8 ± 6.2
SEP 2 at baseline   47.8
SEP 3 at baseline   21.2
Figure 2. Patient disposition.
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3.3  Secondary endpoint analyses: IIEF and SEP
The overall mean IIEF score significantly improved
compared to the baseline for both treatment regimens.  A
sub-analysis of the IIEF domains showed similar improve-
ments for both regimens in all but in the Erectile Function
(IIEF-EF) domain, which improved from 14.80 at the
baseline to 24.67 with the on-demand regimen, and to
25.00 with the three times per week regimen (P = 0.012)
(Figure 3).  The analysis of the single items of IIEF showed
that patients in the three times per week regimen scored
significantly better in the questions on intercourse satis-
faction (P = 0.012), maintenance ease (P = 0.026), pen-
etration ability (P = 0.034), erection firmness (P = 0.006)
and erection frequency (P = 0.034), whereas no differ-
ence was reported in the remaining questions (Figure 4).
Stratifying patients for baseline severity of ED showed
a higher efficacy of the on-demand regimen in patients
with mild ED, whereas the three times per week regimen
was more effective in patients with severe ED (Figure 5).
SEP questionnaire results are shown in Figure 6.  In
response to the SEP3 question (Did your erection last
long enough for you to have successful intercourse?),
the mean per patient success rate improved from 19.6%
at the baseline to 72.9% at the endpoint for the on-de-
mand regimen, and from 19.0% to 75.9% for the three
times per week regimen.
In response to the SEP5 question (Were you satis-
fied overall with this sexual experience?), the mean per
patient rate improved from 6.3% at the baseline to 63.0%
at the endpoint for the on-demand regimen and from
6.2% to 66.0% for the three times per week regimen.
For all SEP questions the improvement reported with the
three times per week regimen was significantly higher
Figure 3. Summary of secondary efficacy variables. International
Index of Erectile Function (IIEF) domains: variations from baseline
to endpoint. Score range of the IIEF domains: intercourse
satisfaction, 0–15; sexual desire, 2–10; orgasmic function, 0–10;
erectile function, 1–30; overall satisfaction, 2–10.  P values are
from a cross-over analysis of variance model that includes treat-
ment regimen, pooled site, patient, baseline value and period. The
model additionally includes baseline-value-by-treatment-regimen
interaction if the latter is significant at P < 0.10. cP < 0.01, com-
pared with D.  D, on-demand regimen; SCH, three times per week
regimen; IIEF, International Index of Erectile Function.
Figure 5. Change from baseline in IIEF-EF domain by baseline
severity stratum. D, on-demand regimen; IIEF, International Index
of Erectile Function; SCH, three times per week regimen.
Figure 4. Summary of secondary efficacy variables. IIEF items:
Variations from baseline to endpoint. P values are from a cross-
over analysis of variance model that includes treatment regimen,
pooled site, patient, baseline value, and period. The model addi-
tionally includes baseline-value-by-treatment-regimen interaction
if the latter is significant at P < 0.10. P-values are for the compari-
son of on-demand (D) versus three times per week (SCH) regimens.
bP < 0.05, cP < 0.01, compared with D. D, on-demand regimen;
SCH, three times per week regimen; IIEF, International Index of
Erectile Function.
.400.
Alternative dosing regimen with tadalafil
http://www.asiaandro.com;  aja@sibs.ac.cn
Table 3. Summary of treatment emergent adverse events (frequency ≥  by decreasing frequency of occurrence. Treatment emergent adverse
events (TEAE) are defined as events that first occurred or worsened after baseline. Baseline TEAE were secondary conditions and events
recorded before randomization. This table shows TEAE with =1% incidence in any period; these are not additive as a single patient may
have reported more than one event. D, on-demand regimen; SCH, three times per week regimen.
TEAE
               D                                                      SCH                                    
 P value n (%)  n (%)
Headache 60 (5.7) 56 (5.3) 0.775
Myalgia 35 (3.3) 45 (4.3) 0.305
Dyspepsia 27 (2.6) 30 (2.8) 0.789
Abdominal pain upper 20 (1.9) 31 (2.9) 0.156
Flushing 18 (1.7) 27 (2.6) 0.228
Back pain 14 (1.1) 10 (0.9) 0.539
Gastritis 12 (1.1) 23 (2.2) 0.087
Figure 6. Sexual encounter variations from baseline to endpoint for
two treatment regimens of 20 mg of tadalafil. Mean per-patient
percentage of “yes” responses to Sexual Encounter Profile (SEP)
questions. SEP1: Were you able to achieve at least some erection
(some enlargement of the penis)? SEP2: Were you able to insert
your penis into your partner’s vagina? SEP3: Did your erection
last long enough for you to have successful intercourse? SEP4:
Were you satisfied with the hardness of your erection?  SEP5: Were
you satisfied overall with this sexual experience? For each variable,
population summarized consists of those patients having both
baseline and at least one postbaseline data. Mean within treatment
regimen of change from baseline to endpoint. P values are from a
cross-over analysis of variance model that includes treatment
regimen, pooled site, patient, baseline value, and period. The model
additionally includes baseline-value-by-treatment-regimen interac-
tion if the latter is significant at P < 0.10. bP < 0.05, cP < 0.01,
compared with D. D, on-demand regimen; SCH, three times per
week regimen; IIEF, International Index of Erectile Function.
than that with the on-demand regimen.
3.4  Adverse events
Both treatment regimens were well tolerated and no
deaths were reported.  Adverse events were rare and
generally mild and caused early discontinuation in 4.6%
of patients (Table 1).  No significant difference in the
incidence of adverse was found comparing the two treat-
ment regimens (Table 3).
4    Discussion
The aim in the treatment of ED is to restore an erec-
tion satisfaction for the needs of the patient.  The PDE5
inhibitors are currently the first therapeutic line in ED
treatment, and all the three available agents, sildenafil,
vardenafil and tadalafil, are effective and safe [4–6].
Actually, there are no data supporting superiority for any
one of them in terms of efficacy or safety, and both
clinician and patient make their choice considering sev-
eral factors related to the sexual activity and the prefer-
ence of the patient and to the peculiar pharmacokinetic
characteristics of these drugs (e.g.  the possible interfer-
ence with alcohol and food and the duration of clinical
effects).
As patient’s reported outcome is the gold-standard
in efficacy evaluation, it is currently widely accepted that
patient’s preference should be regarded as the leading
criterion in the treatment strategy [7, 8].  Several prefer-
ence studies comparing PDE5 inhibitors have been
conducted, but for most of them the interpretation of the
results is affected by important design flaws, including
absence of randomization, non-equivalence of the doses
used for the compared drugs, questionable data analysis,
and period and carryover effects [9].  The SURE study
was a randomized, cross-over trial where two regimens
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of the same drug were compared [3].  This study design
is the best choice for comparative studies, and adds reli-
ability to both the preference and efficacy results obtained.
The SURE study enrolled 4 262 patients in 14 Euro-
pean countries, and showed that tadalafil was equally
effective and well tolerated in both treatment regimens,
and that an unexpectedly high number of patients (42.2%)
preferred the novel three times per week treatment [3].
However, efficacy results showed a slightly higher im-
provement in all SEP questions and in all but one IIEF
domains with the three times per week compared to the
on-demand regimen.  Although statistically significant,
these differences were not considered clinically signifi-
cant by the authors because of the small numerical im-
provement of the scores and the large sample size.
The present analysis of the Italian data subset con-
firms that both regimens provide excellent efficacy and
tolerability, and that in the clinical practice the patient
could choose between the two alternative but equally
effective treatments according to his personal needs and
preference.  However, the finding of a statistically higher
improvement in all SEP questions and in the IIEF-EF
domain score with the three times per week compared
to the on-demand regimen is also confirmed in the present
subsample, which is smaller and geographically more
homogeneous than the whole SURE study dataset.
Furthermore, when patients were stratified for severity
of ED, a superiority of the three times per week regimen
in improving the IIEF-EF domain score was shown in
severe patients, whereas the on-demand regimen was
more effective in mild patients.  However, this differ-
ence was numerically small and hardly perceivable by
patients.  This is confirmed by the preference data
analysis, showing that the baseline severity of ED could
not predict the preference pattern.
Although not big enough to be considered clinically
important, the statistically higher efficacy of the three
times per week regimen is meaningful from a specula-
tive viewpoint.  It has recently been supposed that the
assumption of PDE5 inhibitors on a regular base, pro-
viding at steady serum levels and a higher drug exposure,
might improve the endothelial function of the corpus
cavernosum, therefore enhancing erectile function be-
yond that observed with the on-demand treatment [10].
In our study the mean number of doses per week as-
sumed by patients was 2.33 and 1.89 in the three times
per week and the on-demand regimen, respectively (P 
< 0.001).
Although this has not translated in a clinically higher
efficacy of the three times per week regimen in the over-
all population in study, a wider, perhaps clinically signifi-
cant difference is evident in the subgroup of patients with
severe ED.  It could be hypothesized, then, that severe
patient can benefit more than mild patients from the higher
exposure to tadalafil reported in the three times per week
regimen.  This observation would support a rehabilita-
tive role of tadalafil three times per week in severe ED
and could open new interesting therapeutic perspectives
for the PDE5 inhibitors in the treatment of ED.
In conclusion, the analysis of the Italian dataset of
the SURE study confirms that tadalafil is effective and
well tolerated whether used as a traditional on-demand
treatment or in a novel three times per week regimen.  In
the decision-making process that, through interaction
between clinician’s guide and patient’s preference, leads
to the selection of the optimal treatment of ED, these
observations provide a scenario where not only the drug
but also the treatment regimen can be chosen, further
increasing our ability to tailor treatment to an individual
patient’s needs.
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